Prabhat Hebbar, MD
Clinical Cardiac Electrophysiology · Little Rock, ARNPI 1245215243
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,610 of the $75,121 with a category attached, or 72.7%. Johnson & Johnson accounts for 81.3% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $35,636 and has fallen 93.3% since, to $2,375 in 2025.
Across 538 payments — averaging $139.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$61K
- Medtronic$5K
- Medical Device Business Services, Inc.$2K
- Novartis$2K
- Biosense Webster, Inc.$891
- Abbott$874
- plus $3K from 27 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$54,61073%
- Travel & lodging$9,47413%
- Food & beverage$10,65614%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 117 | $61,037 |
| Medtronic(2 entities) | 50 | $4,928 |
| Medical Device Business Services, Inc. | 8 | $2,067 |
| Novartis | 164 | $2,000 |
| Biosense Webster, Inc. | 22 | $891 |
| Abbott | 16 | $874 |
| Atricure, Inc. | 7 | $559 |
| Pfizer | 31 | $475 |
| Amgen | 18 | $311 |
| Boston Scientific | 6 | $224 |
| Boehringer Ingelheim | 13 | $222 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $215 |
| AstraZeneca | 13 | $172 |
| Alnylam Pharmaceuticals Inc. | 8 | $150 |
| Merck | 8 | $137 |
| Sanofi-aventis U.S. LLC | 7 | $128 |
| Amarin Pharma, Inc. | 7 | $126 |
| Astellas Pharma US Inc | 3 | $116 |
| E.r. Squibb & Sons, L.L.C. | 6 | $92 |
| Actelion Pharmaceuticals US, Inc. | 4 | $74 |
| Elutia, Inc. | 2 | $46 |
| Philips North America LLC | 3 | $43 |
| Kestra Medical Technology Services, Inc. | 1 | $41 |
| Edwards Lifesciences | 1 | $30 |
| Esperion Therapeutics, Inc. | 2 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Cardiva Medical, Inc. | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$59,114
- Micra$1,911
- Carto 3 System$1,495
- EVERA MRI XT DR SURESCAN$885
- Carto 3$703
- ENSITE$428
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$369
- LINQ II$163
- AURORA EV-ICD MRI SURESCAN$120
How this compares
$75,121 in reported general payments places this provider in the 80th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.
See all clinical cardiac electrophysiology providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 303 | $234,504 |
| XareltoRivaroxaban | 265 | $224,643 |
| EntrestoSacubitril/Valsartan | 161 | $150,717 |
| MultaqDronedarone Hcl | 11 | $17,112 |
| JardianceEmpagliflozin | 22 | $12,615 |
| FarxigaDapagliflozin Propanediol | 12 | $12,299 |
| Metoprolol Succinate | 503 | $7,049 |
| Flecainide Acetate | 200 | $5,343 |
| Propafenone Hcl ErPropafenone Hcl | 19 | $4,840 |
| Propafenone Hcl | 103 | $3,447 |
| SotalolSotalol Hcl | 145 | $3,103 |
| Digoxin | 118 | $2,956 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 120 | $2,660 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 44 | $1,982 |
| Metoprolol Tartrate | 370 | $1,963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $475 | $234,504303 claims |
| Johnson & JohnsonXarelto | $61,037 | $224,643265 claims |
| NovartisEntresto | $2,000 | $150,717161 claims |
| Sanofi-aventis U.S. LLCMultaq | $128 | $17,11211 claims |
| Boehringer IngelheimJardiance | $222 | $12,61522 claims |
| AstraZenecaFarxiga | $172 | $12,29912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.
Other clinical cardiac electrophysiology in Little Rock
- Monica LoLittle Rock$190K
- Sudarone ThihalolipavanLittle Rock$77K
- Gerald GreerLittle Rock$41K
- Risheek KaulLittle Rock$38K
- Michael LoguidiceLittle Rock$29K
- Breck SandvallLittle Rock$23K
- Brian NorrisLittle Rock$18K
- Thomas WallaceLittle Rock$14K
- Subodh DevabhaktuniLittle Rock$9K
- van de BruynLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.